Skip to main content
Premium Trial:

Request an Annual Quote

Epic Sciences Raises $13M in Series B Round

NEW YORK (GenomeWeb News) – Epic Sciences today announced it has completed its Series B financing round raising $13 million.

Proceeds will go toward expanding the San Diego-based firm's R&D operations and capabilities to commercialize its platform for the molecular characterization of circulating tumor cells in blood. The technology is licensed from Peter Kuhn's laboratory at The Scripps Research Institute.

Epic currently has collaborations with seven pharmaceutical firms to develop companion diagnostics for oncology drug candidates, it said, including a number of partnerships in Phase I and II clinical trials.

The Series B round includes new investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as unnamed individual investors. Kim Kamdar, a partner in Domain, is joining Epic's board in conjunction with the financing, Epic said.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.